Biden's Proposal Boosts Novo Nordisk Shares Amid Obesity Drug Debate
Novo Nordisk's shares rose due to President Joe Biden's proposal to expand Medicare and Medicaid coverage for anti-obesity drugs. While current rules exclude obesity-specific drugs, this proposal could lower costs and increase access.
Wall Street Journal on MSN9h
Novo Nordisk Says White House Obesity Plan Is Step in Right DirectionNovo Nordisk is encouraged by White House proposals that could support patients using weight-loss drugs, but cautioned ...
Novo Nordisk Foundation CEO Mads Krogsgaard Thomsen said only 9 million people are using GLP-1s compared with 1 billion ...
The world’s largest philanthropic fund that ultimately controls Novo Nordisk A/S will ramp up its investments outside of ...
Novo Nordisk faces challenges in weight-loss sector, but acquisition and strong diabetes portfolio position it for future ...
Novo Nordisk stock has been pretty volatile lately, making it hard to judge whether now is a good opportunity to buy shares.
According to Reuters and CNN, Novo Nordisk announced Monday that it has launched its popular obesity drug Wegovy in China ...
Novo Nordisk will report the topline results from the REDEFINE-1 trial of CagriSema in obese patients before the end of the ...
More than 200,000 prescriptions for copies of Novo Nordisk's weight-loss drug Wegovy are getting filled by U.S. patients each ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback